Astellas and Pfizer Global Medical Grants

Call for Independent Quality Improvement Grant Applications
Oncology – Prostate Cancer

Release Date: November 15, 2022

I. Background

Astellas and Pfizer (collectively, the Companies) are committed to supporting high quality, evidence-based Quality Improvement Grants (QI) that seek to improve the overall safety and quality of patient care and treatment for patients with Prostate Cancer (PC).

The intent of this QI Call for Grant Applications (CGA) is to encourage the submission of proposals describing concepts and ideas to measurably improve the quality of care for patients with prostate cancer relative to guideline-based management for men with metastatic hormone sensitive prostate cancer (mHSPC) in health systems, cancer care centers, or networks.

Proposals that have the most potential to directly impact the quality of care for patients with mHSPC in the US will be prioritized.

The sustainability and broad applicability of the approach will be key factors in evaluating funded projects.

II. Scope / Areas of Interest

Astellas and Pfizer are committed to funding US-based projects that:

• Bring the healthcare team together, including innovative organizations, to understand gaps in practice and develop strategies to improve care/close gaps.
• Further identify quality and performance gaps in the treatment of mHSPC with deeper analyses and understanding of the gaps and needs of those targeted and/or included in the intervention. These can encompass a broad set of areas. Needs may include improved provider knowledge regarding clinical aspects of guideline-based, standard-of-care (SOC) treatments for mHSPC, and extend to organizational, logistical, as well as technological gaps.
• Educate health care systems and providers to engage patients, their caregivers, and families in shared decision-making regarding management of mHSPC.
• Use evidence-based educational strategies that are aligned with the desired results of guideline-based, SOC treatments and interventions.

Areas of interest can include:

1) Optimal guideline-based treatment strategies for patients with mHSPC.
2) Delivering optimal treatment wherever there is a point of mHSPC patients contact.
3) Leveraging a multi-disciplinary team approach to improve patient quality of care.
4) Therapy management.
5) Health care professionals, healthcare managers education in terms of clinical and outcomes research in the assessment of treatment options vs healthcare systems sustainability to optimize mHSPC treatment strategies for patients. This can include incorporation of new technologies to enhance the quality of healthcare services delivery to patients with mHSPC.
6) Healthcare provider, patient education, shared treatment goals, and engagement in decision making.

7) Patient adherence with mHSPC treatments.

Submissions addressing topics in addition to those listed above will be considered. A plan for long-term sustainability should be included within the submission.

Positive patient Impact on diverse populations is not a singular requirement of this grant opportunity; however, projects that have the greatest impact on multiple patient populations, including those most deeply affected by PC will be favored.

The Companies do not have influence over any aspect of the supported projects and request quarterly interim outcomes reports including a description of the impact of the projects and a final reconciliation report.

When responding to this CGA, please adhere to the following principles in addition to the established guidelines for the Astellas grant application process.

All applications must be submitted online through the Astellas Grant Management System, accessible at www.astellasgrants.com.

III. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>United States Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant Eligibility Criteria:</td>
<td>Eligible applicants include hospitals, academic medical centers and medical schools, national-level professional medical associations/societies, health systems, cancer care centers or networks. Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations are strongly encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project. Where a program is offering continuing education credit, the requesting organization must be the accredited grantee.</td>
</tr>
</tbody>
</table>
## IV. Requirements

<table>
<thead>
<tr>
<th>Date CGA Issued</th>
<th>November 15, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Deadline</td>
<td>January 13, 2023</td>
</tr>
<tr>
<td>Anticipated Grant Decision Date</td>
<td>March 1, 2023</td>
</tr>
<tr>
<td>Clinical Area- Education</td>
<td>Oncology – Prostate Cancer</td>
</tr>
</tbody>
</table>

### Specific Education Gaps To Be Addressed

The purpose of this CGA is to encourage organizations to submit grant application proposals describing concepts and ideas to measurably improve the quality of care received by patients diagnosed with mHSPC in health systems, cancer care centers or pertinent networks (including public healthcare landscape).

Projects should aim to improve the implementation of guideline-based care and use optimal measures to improve care for patients with mHSPC, where treatment goals focus on improving length of life.

Multiple factors contribute to the complexity of treating mHSPC including the need for cross-functional involvement in care; the rapidly changing options for treatment strategies; managing treatment and disease side effects; communicating with patients, caregivers and family members.

Supporting health care professionals in their efforts to maintain and improve their knowledge, ability, and performance related to treating patients with mHSPC is critical to improving patient care. The quality of care that health care professionals provide takes place in complex systems that are often in need of continuous assessment to allow for more efficient and appropriate patient care.

**GAPS IN CLINICAL PRACTICE:** A gap in clinical practice is considered to be the difference between current practice and the optimal care.

Gaps are associated with a combination of:

- Clinician factors (knowledge, competencies, attitudes or preferences)
- Patient factors (access to care, clinical characteristics, comorbid conditions, preferences, work, family)
- Clinician and patient communication

Gaps in clinical practice may relate to the ability or competencies of the health care professionals themselves, the abilities or competencies of the systems in which they work, or other factors related to the external environment or patient population.

This CGA seeks to provide funding to projects that, ultimately, are aimed at helping health care providers deliver the best care to each patient at the appropriate time. **Priority will be given to grant proposals which address multiple gaps from the above list.**
| **How to Submit** | Please go to [www.astellasgrants.com](http://www.astellasgrants.com) and sign in. First-time users should click “REGISTER NOW”. Select the following:  
Therapeutic Area: Oncology  
Disease State: Prostate Cancer  
Requirements for submission:  
You must include “2022CGA01” in the “Activity Title” of your program’s online submission prior to the title.  
Complete all required sections of the online application and upload the Completed proposal.  
If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page.  
**IMPORTANT:** Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed. |
| **Target Audiences** | Healthcare professionals responsible for the treatment decisions for patients with prostate cancer, including urologists, medical oncologists, radiation oncologists |
| **Expected Approximate Monetary Range of Grant Applications** | Collectively, **$600,000** is available for award. Individual requests up to **$200,000** will be considered for funding. Smaller grant budgets are encouraged. Astellas strongly encourages applicants to seek funding from multiple sources.  
The amount of any grant funded by the Companies for any project may vary from the amount requested. |
IV. Terms and Conditions

1. This CGA does not commit the Companies or their partners to award a grant or a grant of any particular amount if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.

2. The Companies reserve the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety at any time for any reason.

3. All communications about the CGA must be sent to Astellas at http://www.astellasgrants.com/. Applicants should not contact other departments within Astellas regarding this CGA. Failure to comply may affect the acceptance of your application.

4. The decision by the Companies to provide a grant will not be determined in a manner that takes into account the volume or value of any business otherwise generated between Astellas or Pfizer and any applicant.

5. Applicant shall have complete control over the content, development and implementation of the education programs and/or materials, including, if applicable, the selection of faculty. Any information provided as part of the program regarding any products, including, without limitation, Astellas and/or Pfizer products, shall be objective and based on scientific methods generally accepted in the medical community.

6. US Transparency Reporting

   A. To enable Astellas to comply with its legal obligations, in the event that any payment or other transfer of value (hereinafter “payment” or “payments”) is provided, either directly or indirectly, to a covered recipient (as defined below) or to another individual or entity at the request or on behalf of a covered recipient, in connection with an approved grant request, Eligible applicants shall implement procedures to track the payments and shall report the payments to Astellas upon grant reconciliation and in accordance with any written instructions that Astellas may provide to them. Required reporting information includes, but shall not be limited to:

   a. Name and primary business address of covered recipient
   b. For physician covered recipient, NPI, state professional license number and specialty.
   c. Amount of payment
   d. Date of payment
   e. Form of payment
   f. Nature of payment
B. In addition to these tracking and reporting obligations, eligible applicants shall inform such covered recipient at the time of payment that his/her/its acceptance of such payment may be disclosed in a report filed with government authorities by Astellas as required by law and that government authorities may make the reported information publicly available.

C. For purposes of this Agreement, the term “covered recipient” has the meaning ascribed to it in 42 C.F.R. § 403.902 and any similar state law which requires tracking and reporting of payments to a government agency for payment transparency purposes.